Kim JH, Noh J, Kim W, Seong H, Kim JH, Lee WJ, et al. Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls: a nationwide population-based study in South Korea. HIV Med. 2021;22:824–33. https://doi.org/10.1111/hiv.13139.

Article  PubMed  Google Scholar 

Biver E. Osteoporosis and HIV infection. Calcif Tissue Int. 2022;110:624–40. https://doi.org/10.1007/s00223-022-00946-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stone B, Dockrell D, Bowman C, McCloskey E. HIV and bone disease. Arch Biochem Biophys. 2010;503:66–77. https://doi.org/10.1016/j.abb.2010.07.029.

Article  CAS  PubMed  Google Scholar 

Starup-Linde J, Rosendahl SB, Storgaard M, Langdahl B. Management of osteoporosis in patients living with HIV-A systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2020;83:1–8. https://doi.org/10.1097/QAI.0000000000002207.

Article  PubMed  Google Scholar 

Han WM, Wattanachanya L, Apornpong T, Jantrapakde J, Avihingsanon A, Kerr SJ, et al. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: a five-year prospective study. PLoS ONE. 2020;15:e0230368. https://doi.org/10.1371/journal.pone.0230368.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McComsey GA, Lupo S, Parks D, Poggio MC, De Wet J, Kahl LP, et al. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS. 2018;32:477–85. https://doi.org/10.1097/QAD.0000000000001725.

Article  CAS  PubMed  Google Scholar 

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1:CD001155. https://doi.org/10.1002/14651858.CD001155.pub2.

Article  Google Scholar 

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65. https://doi.org/10.1056/NEJMoa0809493.

Article  CAS  PubMed  Google Scholar 

Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, Stoneman JS, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38:426–31. https://doi.org/10.1097/01.qai.0000145352.04440.1e.

Article  CAS  PubMed  Google Scholar 

Negredo E, Martínez-López E, Paredes R, Rosales J, Pérez-Alvarez N, Holgado S, et al. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS. 2005;19:343–5.

CAS  PubMed  Google Scholar 

Fardellone P, Lello S, Cano A, de Sá Moreira E, Watanabe de Oliveira R, Julian GS, et al. Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review. Clin Ther. 2019;41:1576–88. https://doi.org/10.1016/j.clinthera.2019.05.001.

Article  CAS  PubMed  Google Scholar 

Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23:317–26. https://doi.org/10.1007/s00198-011-1780-1.

Article  CAS  PubMed  Google Scholar 

Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int. 2011;22:1725–35. https://doi.org/10.1007/s00198-010-1378-z.

Article  CAS  PubMed  Google Scholar 

Lyu H, Yoshida K, Zhao SS, Wei J, Zeng C, Tedeschi SK, et al. Delayed denosumab injections and fracture risk among patients with osteoporosis: A population-based cohort study. Ann Intern Med. 2020;173:516–26. https://doi.org/10.7326/M20-0882.

Article  PubMed  Google Scholar 

Huang CF, Shiao MS, Mao TY. Retrospective analysis of the effects of non-compliance with denosumab on changes in bone mineral density during the COVID-19 pandemic. Patient Prefer Adherence. 2021;15:1579–84. https://doi.org/10.2147/PPA.S316144.

Article  PubMed  PubMed Central  Google Scholar 

Betella N, Biamonte E, Matarazzo C, Piccini S, Olivetti R, Cellini M, et al. Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab. Minerva Endocrinol. 2020;45:165–71. https://doi.org/10.23736/S0391-1977.20.03137-5.

Article  PubMed  Google Scholar 

Makras P, Petrikkos P, Anastasilakis AD, Kolynou A, Katsarou A, Tsachouridou O, et al. Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients. Bone Rep. 2021;15:101128. https://doi.org/10.1016/j.bonr.2021.101128.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marasco E, Mussa M, Motta F, Bobbio-Pallavicini F, Maserati R, Montecucco C, et al. Denosumab for the treatment of HIV-associated osteoporosis with fractures in a premenopausal woman. Reumatismo. 2021;73:54–8. https://doi.org/10.4081/reumatismo.2021.1358.

Article  CAS  PubMed  Google Scholar 

Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26:2479–89. https://doi.org/10.1007/s00198-015-3164-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sato K, Mano T, Niimi Y, Iwata A, Toda T, Iwatsubo T. The impact of COVID-19 pandemic on the utilization of ambulatory care for patients with chronic neurological diseases in Japan: evaluation of an administrative claims database. BioSci Trends. 2021;15:219–30. https://doi.org/10.5582/bst.2021.01194.

Article  CAS  PubMed  Google Scholar 

Osawa I, Goto T, Asami Y, Itoh N, Kaga Y, Yamamoto Y, et al. Physician visits and medication prescriptions for major chronic diseases during the COVID-19 pandemic in Japan: retrospective cohort study. BMJ (Open). 2021;11:e050938. https://doi.org/10.1136/bmjopen-2021-050938.

Article  PubMed  Google Scholar 

Fahrleitner-Pammer A, Papaioannou N, Gielen E, Feudjo Tepie M, Toffis C, Frieling I, et al. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. Arch Osteoporos. 2017;12:58. https://doi.org/10.1007/s11657-017-0351-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4:643–6. https://doi.org/10.1136/bmj.4.5893.643.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berry SD, McLean RR, Hannan MT, Cupples LA, Kiel DP. Changes in bone mineral density may predict the risk of fracture differently in older adults according to fall history. J Am Geriatr Soc. 2014;62:2345–9. https://doi.org/10.1111/jgs.13127.

Article  PubMed  PubMed Central  Google Scholar 

Bolognese MA, Teglbjærg CS, Zanchetta JR, Lippuner K, McClung MR, Brandi ML, et al. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the freedom study. J Clin Densitom. 2013;16:147–53. https://doi.org/10.1016/j.jocd.2012.02.006.

Article  PubMed  Google Scholar 

Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, et al. Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int. 2022;33:1243–56. https://doi.org/10.1007/s00198-021-06174-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Ström O. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int. 2015;26:2401–11. https://doi.org/10.1007/s00198-015-3253-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H, et al. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int. 2016;27:2967–78. https://doi.org/10.1007/s00198-016-3623-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petranova T, Boyanov M, Shinkov A, Petkova R, Intorcia M, Psachoulia E. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates. Arch Osteoporos. 2017;13:1. https://doi.org/10.1007/s11657-017-0413-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morley J, Moayyeri A, Ali L, Taylor A, Feudjo-Tepie M, Hamilton L, et al. Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK clinical practice research datalink. Osteoporos Int. 2020;31:533–45. https://doi.org/10.1007/s00198-019-05228-8.

Article  CAS  PubMed  Google Scholar 

Pedersen AB, Risbo N, Kafatos G, Neasham D, O’Kelly J, Ehrenstein V. Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study. Arch Osteoporos. 2023;18:19. https://doi.org/10.1007/s11657-023-01210-4.

Article  PubMed  PubMed Central